17:33 EST TuHURA Biosciences (HURA) files $250M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences Plans Phase 2 Trial for TBS-2025
- TuHURA Biosciences Secures $3M Bridge Loan Agreement
- Tuhura Biosciences Advances in Merkel Cell Carcinoma Treatment Study
- Tuhura Biosciences’ Promising Phase 1 Trial: A Potential Game-Changer in Merkel Cell Carcinoma Treatment
- TuHURA Biosciences Extends Warrant Expiration to 2030